Chemotherapy re-challenge response rate in metastatic colorectal cancer
نویسندگان
چکیده
منابع مشابه
The Challenge of Metastatic Colorectal Cancer
Colorectal cancer (CRC) is a very common disease with a high rate of mortality around the world, representing the second most frequent cause of cancer-related death. As the majority of patients are diagnosed with advanced cancer with a subsequent low five-year survival rate (10%), it is imperative to develop new strategies to treat this challenging patient population. Traditionally, patients re...
متن کاملIntrahepatic Chemotherapy 2 for Metastatic Colorectal Cancer
Colorectal cancer (CRC) is the fourth most common malignancy in the United States (1). Approximately 130,000 new patients will be diagnosed with this cancer in 1999. It is the second leading cause of cancer death, with 55,000 patients expected to die of it. Most patients die of metastatic disease. The vast majority of them have liver as the dominant site of metastases (2). Approximately 30% of ...
متن کاملChemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer.
BACKGROUND Fluoropyrimidine-based chemotherapy plus the anti-vascular endothelial growth factor (VEGF) antibody bevacizumab is standard first-line treatment for metastatic colorectal cancer. We studied the effect of adding the anti-epidermal growth factor receptor (EGFR) antibody cetuximab to a combination of capecitabine, oxaliplatin, and bevacizumab for metastatic colorectal cancer. METHODS...
متن کاملCombining chemotherapy and targeted therapies in metastatic colorectal cancer.
Colorectal cancer remains one of the major causes of cancer death worldwide. During the past years, the development of new effective treatment options has led to a considerable improvement in the outcome of this disease. The advent of agents such as capecitabine, irinotecan, oxaliplatin, erbitux and bevacizumab has translated into median survival times in the range of 2 years. Intense efforts h...
متن کاملProlonged survival in metastatic colorectal cancer following chemotherapy
KEY CLINICAL MESSAGE The cost of treating metastatic colorectal cancer has increased significantly after the introduction of targeted antivascular therapies. We report the unusual case of a patient with colorectal cancer with several large liver metastases at diagnosis, who was cured after removal of the primary tumor and treatment with 5-FU/LV only.
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Gastrointestinal Oncology
سال: 2018
ISSN: 2078-6891,2219-679X
DOI: 10.21037/jgo.2018.04.08